Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022
31 oct. 2022 16h05 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting new data from its hepatitis B virus (HBV) clinical program...
Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
11 oct. 2022 16h03 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., executive vice president, chief medical officer and interim head...
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD The Liver Meeting®
12 nov. 2021 08h00 HE
|
Vir Biotechnology, Inc.
– New data from ongoing trials evaluating Vir’s two novel HBV therapies continue to demonstrate notable reductions in HBsAg and support their positive safety profiles – SAN FRANCISCO, Nov. 12, 2021 ...
Vir Biotechnology to Participate in the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
06 oct. 2021 16h05 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the H. C....